Department of Otolaryngology, Louisiana State University, Baton Rouge, Louisiana, USA.
Department of Otolaryngology, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA.
Head Neck. 2021 May;43(5):1509-1520. doi: 10.1002/hed.26601. Epub 2021 Jan 8.
Immunotherapy agents are used to treat advanced head and neck lesions. We aim to elucidate relationship between immunotherapy and surgical wound complications.
Retrospective multi-institutional case series evaluating patients undergoing ablative and flap reconstructive surgery and immunotherapy treatment.
wound complications.
Eight-two (62%) patients received preoperative therapy, 89 (67%) postoperative, and 33 (25%) in both settings. Forty-one (31%) patients had recipient site complications, 12 (9%) had donor site. Nineteen (14%) had major recipient site complications, 22 (17%) had minor. There was no statistically significant difference in complications based on patient or tumor-specific variables. Preoperative therapy alone demonstrated increased major complications (odds ratio [OR] 3.7, p = 0.04), and trend to more donor site complications (OR 7.4, p = 0.06), however treatment in both preoperative and postoperative therapy was not.
Preoperative immunotherapy may be associated with increased wound complications. Controlled studies are necessary to delineate this association and potential risks of therapy.
免疫疗法药物被用于治疗晚期头颈部病变。我们旨在阐明免疫疗法与手术伤口并发症之间的关系。
回顾性多机构病例系列研究，评估接受消融和皮瓣重建手术以及免疫治疗的患者。
伤口并发症。
82 例（62%）患者接受术前治疗，89 例（67%）接受术后治疗，33 例（25%）患者同时接受两种治疗。41 例（31%）患者出现受区并发症，12 例（9%）患者出现供区并发症。19 例（14%）患者出现主要受区并发症，22 例（17%）患者出现次要受区并发症。根据患者或肿瘤特异性变量，并发症无统计学显著差异。单独接受术前治疗的患者出现主要并发症的风险增加（优势比[OR]3.7，p=0.04），且有更多供区并发症的趋势（OR 7.4，p=0.06），但术前和术后同时接受治疗则无此风险。
术前免疫治疗可能与增加的伤口并发症相关。需要进行对照研究以阐明这种关联和治疗的潜在风险。
